Compare PROP & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROP | VANI |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.6M | 95.8M |
| IPO Year | 2008 | 2014 |
| Metric | PROP | VANI |
|---|---|---|
| Price | $1.75 | $1.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $6.75 | $4.00 |
| AVG Volume (30 Days) | ★ 1.1M | 430.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.95 | 14.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,939,000.00 | $4,000,000.00 |
| Revenue This Year | $3,546.93 | N/A |
| Revenue Next Year | $84.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 413.59 | N/A |
| 52 Week Low | $1.57 | $0.91 |
| 52 Week High | $7.77 | $1.92 |
| Indicator | PROP | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 44.22 |
| Support Level | $1.66 | $1.20 |
| Resistance Level | $1.93 | $1.24 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 27.16 | 33.33 |
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.